NZ508770A - Textilinin plasmin inhibitors from the Australian brown snake pseudonaja textilis textilis - Google Patents

Textilinin plasmin inhibitors from the Australian brown snake pseudonaja textilis textilis

Info

Publication number
NZ508770A
NZ508770A NZ508770A NZ50877099A NZ508770A NZ 508770 A NZ508770 A NZ 508770A NZ 508770 A NZ508770 A NZ 508770A NZ 50877099 A NZ50877099 A NZ 50877099A NZ 508770 A NZ508770 A NZ 508770A
Authority
NZ
New Zealand
Prior art keywords
glu
leu
cys
gly
pro
Prior art date
Application number
NZ508770A
Other languages
English (en)
Inventor
Pantaleone Paul Masci
Martin Francis Lavin
Patrick Joseph Gaffney
Original Assignee
Univ Queensland
Nat Inst Ofbiological Standard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland, Nat Inst Ofbiological Standard filed Critical Univ Queensland
Publication of NZ508770A publication Critical patent/NZ508770A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ508770A 1998-05-11 1999-05-07 Textilinin plasmin inhibitors from the Australian brown snake pseudonaja textilis textilis NZ508770A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP3450A AUPP345098A0 (en) 1998-05-11 1998-05-11 Novel anti-fibrinolytic agents
PCT/AU1999/000343 WO1999058569A1 (en) 1998-05-11 1999-05-07 PLASMIN INHIBITORS FROM THE AUSTRALIAN BROWN SNAKE $i(PSEUDONAJA TEXTILIS TEXTILIS)

Publications (1)

Publication Number Publication Date
NZ508770A true NZ508770A (en) 2003-12-19

Family

ID=3807704

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ508770A NZ508770A (en) 1998-05-11 1999-05-07 Textilinin plasmin inhibitors from the Australian brown snake pseudonaja textilis textilis

Country Status (11)

Country Link
US (1) US7070969B1 (enExample)
EP (1) EP1078003B1 (enExample)
JP (1) JP4542705B2 (enExample)
AT (1) ATE440108T1 (enExample)
AU (1) AUPP345098A0 (enExample)
CA (1) CA2328431C (enExample)
DE (1) DE69941292D1 (enExample)
DK (1) DK1078003T3 (enExample)
ES (1) ES2332249T3 (enExample)
NZ (1) NZ508770A (enExample)
WO (1) WO1999058569A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP345098A0 (en) * 1998-05-11 1998-06-04 National Institute Of Biological Standards And Control, United Kingdom Novel anti-fibrinolytic agents
US6506365B1 (en) * 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
US7745192B2 (en) 2002-04-03 2010-06-29 Venomics Pty Limited Prothrombin activating protein
ES2431526T3 (es) 2005-12-29 2013-11-26 The Regents Of The University Of California Office Of Technology Transfer Procedimientos y composiciones relacionadas con el dominio Kunitz I mutante de TFPI-2
EP2154152A1 (en) * 2008-08-08 2010-02-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of Conkunitzin-S1 for the modulation of glucose-induced insulin secretion
EP2359852A4 (en) * 2008-11-17 2015-05-20 Nat Cancer Ct NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND
CN102850451B (zh) * 2011-06-29 2014-05-07 辽宁诺康生物制药有限责任公司 具有抑制纤溶酶活性的重组textilinin-1及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
EP0585504A1 (en) * 1992-09-04 1994-03-09 Pentapharm A.G. Phospholipid dependant prothrombin activator and its use in lupus anticoagulant testing
AUPP076797A0 (en) * 1997-12-05 1998-01-08 Active (Pla) R&D Pty Ltd Phospholipase inhibitor
AUPP345098A0 (en) * 1998-05-11 1998-06-04 National Institute Of Biological Standards And Control, United Kingdom Novel anti-fibrinolytic agents

Also Published As

Publication number Publication date
EP1078003A4 (en) 2004-08-25
DE69941292D1 (de) 2009-10-01
JP2002514404A (ja) 2002-05-21
ES2332249T3 (es) 2010-01-29
EP1078003B1 (en) 2009-08-19
US7070969B1 (en) 2006-07-04
ATE440108T1 (de) 2009-09-15
CA2328431C (en) 2010-04-27
DK1078003T3 (da) 2009-12-07
AUPP345098A0 (en) 1998-06-04
JP4542705B2 (ja) 2010-09-15
EP1078003A1 (en) 2001-02-28
WO1999058569A1 (en) 1999-11-18
CA2328431A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
JP3122127B2 (ja) 抗凝血タンパク質
KR100278036B1 (ko) 사람 쿠니즈형 프로테아제 저해제 변이체
JP2655752B2 (ja) 組換えヒト第▲viii▼因子誘導体
AU643306B2 (en) Anticoagulant polypeptides
JPH02121934A (ja) 組合せ医薬組成物
CZ164494A3 (en) Human variant of kunitz-type protease inhibitor
CA2130900C (en) Therapeutic domains of von willebrand factor
JPWO1992000325A1 (ja) 抗血液凝固活性を有するポリペプチド
CZ164694A3 (en) Human variant of kunitz-type protease inhibitor
HUT75358A (en) Methods of prouducing effective recombinant serine protease inhibitors and uses of these inhibitors
Shirasawa et al. Molecular cloning and characterization of prolyl endopeptidase from human T cells
Filippovich et al. A family of textilinin genes, two of which encode proteins with antihaemorrhagic properties
CA2328431C (en) Plasmin inhibitors from the australian brown snake pseudonaja textilis textilis
AU759190B2 (en) Plasmin inhibitors from the Australian brown snake (Pseudonaja textilis textilis)
KR20070036057A (ko) 코브라 베놈 인자-유사 기능을 갖는 사람 보체 c3 유도체
WO2004072240A2 (en) Antiplasmin cleaving enzyme
HU220301B (hu) Véralvadásgátló protosztómiák (vérszívók) nyálából
US5328997A (en) Processes for making proteins having anticoagulant properties
JPH1080281A (ja) 新規蛋白質及びその製造方法
US6369031B1 (en) Protein Z-dependent protease inhibitor
US5679770A (en) Polypeptide, DNA fragment encoding the same, drug composition containing the same and process for producing the same
JPH08510903A (ja) 蛭ヒルド・メディシナリスの組換えxa因子インヒビターの作製
JP2005513141A (ja) 修飾トリデジン(tridegins)、その製剤、およびトランスグルタミナーゼ阻害剤としてのその使用
JP2824418B2 (ja) トロンビンによるプロテインcの活性化を促進する作用を有するペプチドを含有する医薬組成物
HU215532B (hu) Eljárás trombinkötő anyag előállítására

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: VENOMICS PTY LIMITED, AU

Free format text: OLD OWNER(S): THE UNIVERSITY OF QUEENSLAND; NATIONAL INSTITUTE OF BIOLOGICAL STANDARDS AND CONTROL